ID   INA-6.Tu1
AC   CVCL_0C40
SY   Tu1
DR   cancercelllines; CVCL_0C40
DR   Wikidata; Q54897701
RX   PubMed=19621390;
CC   Population: Caucasian.
CC   Characteristics: Produces IgG kappa.
CC   Characteristics: IL6 dependent.
CC   Characteristics: Derived from a tumor that grew in a SCID mouse.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Met (c.395A>T); ClinVar=VCV000376629; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5209 ! INA-6
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=19621390; DOI=10.1002/ijc.24758;
RA   Guenther A., Gordon S., Tiemann M., Burger R., Bakker F., Green J.R.,
RA   Baum W., Roelofs A.J., Rogers M.J., Gramatzki M.;
RT   "The bisphosphonate zoledronic acid has antimyeloma activity in vivo
RT   by inhibition of protein prenylation.";
RL   Int. J. Cancer 126:239-246(2010).
//